Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

中文翻译：

---

阿非卡坦可减轻梗阻性肥厚性心肌病的症状


SEQUOIA-HCM 试验的数据显示，心肌肌球蛋白抑制剂阿菲卡坦可以提高有症状的梗阻性肥厚型心肌病患者的运动能力并改善生活质量。